SL-01
| Code | Size | Price |
|---|
| TAR-T19779-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
SL-01 is an oral derivative of gemcitabine. SL-01 inhibited human breast cancer growth through the induction of apoptosis. SL-01 inhibited human cancer growth more potently than gemcitabine.
CAS:
26049-94-5
Formula:
C18H18ClNO3
Molecular Weight:
331.8
Purity:
0.98
SMILES:
ClCC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1
References
1. Zhao C, Li Y, Qin Y, Wang R, Li G, Sun C, Qu X, Li W. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. Cancer Chemother Pharmacol. 2013 Jun;71(6):1541-50. doi: 10.1007/s00280-013-2153-6. Epub 2013 Apr 6. PubMed PMID: 23564376.
2. Li YY, Qin YZ, Wang RQ, Li WB, Qu XJ. SL-01, an oral derivative of gemcitabine, inhibited human breast cancer growth through induction of apoptosis. Biochem Biophys Res Commun. 2013 Aug 23;438(2):402-9. doi: 10.1016/j.bbrc.2013.07.087. Epub 2013 Jul 27. PubMed PMID: 23899521.
3. Zhao C, Yue B, Liu H, Sun C, Li W, Qu X. SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):293-300. doi: 10.1016/j.taap.2012.05.006. Epub 2012 May 19. PubMed PMID: 22617428.
4. Baptista CJ, Dourado I, de Andrade TM, Brignol S, Bertoni N, Bastos FI; Brazilian Multicity Study Group on Drug Misuse. HIV Prevalence, Knowledge, Attitudes, and Practices Among Polydrug Users in Brazil: A Biological Survey Using Respondent Driven Sampling. AIDS Behav. 2017 May 31. doi: 10.1007/s10461-017-1812-8. [Epub ahead of print] PubMed PMID: 28567550.